|High / Low range:||2.22|
Replimune Announces Poster Presentation at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting
WOBURN, Mass., May 16, 2019 (GLOBE NEWSWIRE) -- Replimune
Group Inc. (NASDAQ: REPL), a biotechnology company developing
oncolytic immuno-gene therapies derived from its Immulytic™
platform, today announced that a trial in progress (TiP)
poster will be presented at the 2019 American Society of
Clinical Oncology (ASCO) Annual Meeting being held in
Chicago, IL from May 31 to June 4, 2019. The abstract is
available on the ASCO website (https://meetinglibrary.asco.org/record/176374/abstract).
The poster will describe the design and current status of the
Company’s ongoing Phase 1/2 clinical trial in approximately
150 patients of RP1 alone and in combination with nivolumab
anti-PD1 therapy in four solid tumor types, and will be made
available on the Company’s website at the time of
Details of Replimune’s poster presentation:
Abstract Title: An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination with PD1 Blockade in Patients with Solid Tumors (Abstract TPS2671)
Session Title: Developmental Immunotherapy and Tumor Immunobiology
Session Date and Time: Saturday June 1st, 8:00am-11:00am CDT
Location: McCormick Place, Exhibit Hall A, Poster Board #301b
RP1 is Replimune’s first Immulytic™ product candidate to enter the clinic and is based on a proprietary new strain of herpes simplex virus engineered to maximize tumor killing potency, the immunogenicity of tumor cell death and the activation of a systemic anti-tumor immune response.
Replimune Group Inc., headquartered in Woburn, MA, was founded in 2015 to develop the next generation of “oncolytic immune-gene therapies” for the treatment of cancer. Replimune is developing novel, proprietary therapeutics intended to improve the direct cancer-killing effects of selective virus replication and the potency of the immune response to the tumor antigens released. The Company’s Immulytic™ platform is designed to maximize systemic immune activation, in particular to tumor neoantigens, through robust viral-mediated immunogenic tumor cell killing and the delivery of optimal combinations of immune-activating proteins to the tumor and draining lymph nodes. The approach is expected to be highly synergistic with immune checkpoint blockade and other approaches to cancer treatment. Replimune intends to progress these therapies rapidly through clinical development in combination with other immuno-oncology products with complementary mechanisms of action. For more information, please visit www.replimune.com
Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding our expectations about our advancement of our clinical trials, our goals to develop and commercialize our product candidates, our proposed scientific presentations, and other statements identified by words such as “could,” “expects,” “intends,” “may,” “plans,” “potential,” “should,” “will,” “would,” or similar expressions and the negatives of those terms. Forward-looking statements are not promises or guarantees of future performance, and are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in such forward-looking statements. These factors include risks related to our limited operating history, our ability to generate positive clinical trial results for our product candidates, the costs and timing of establishing, equipping, and operating our planned in-house manufacturing facility, the timing and scope of regulatory approvals, changes in laws and regulations to which we are subject, competitive pressures, our ability to identify additional product candidates, and other risks set forth under the heading “Risk Factors” of our Quarterly Report on Form 10-Q for the third quarter ended December 31, 2018. Our actual results could differ materially from the results described in or implied by such forward-looking statements. Forward-looking statements speak only as of the date hereof, and, except as required by law, we undertake no obligation to update or revise these forward-looking statements.
Pamela Esposito, Ph.D.
Replimune Group Inc.
Verge Scientific Communications
GlobeNewswire, a Nasdaq company, is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.